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Methicillin-resistant Staphylococcus aureus (MRSA) is a frequent 
cause of difficult-to-treat, often fatal infections in humans1,2. Most 
humans have antibodies against S. aureus, but these are highly 
variable and often not protective in immunocompromised patients3. 
Previous vaccine development programs have not been successful4. 
A large percentage of human antibodies against S. aureus target wall 
teichoic acid (WTA), a ribitol-phosphate (RboP) surface polymer 
modified with N-acetylglucosamine (GlcNAc)5,6. It is currently 
unknown whether the immune evasion capacities of MRSA are due 
to variation of dominant surface epitopes such as those associated 
with WTA. Here we show that a considerable proportion of the 
prominent healthcare-associated and livestock-associated MRSA 
clones CC5 and CC398, respectively, contain prophages that encode 
an alternative WTA glycosyltransferase. This enzyme, TarP, transfers 
GlcNAc to a different hydroxyl group of the WTA RboP than the 
standard enzyme TarS7, with important consequences for immune 
recognition. TarP-glycosylated WTA elicits 7.5–40-fold lower levels 
of immunoglobulin G in mice than TarS-modified WTA. Consistent 
with this, human sera contained only low levels of antibodies against 
TarP-modified WTA. Notably, mice immunized with TarS-modified 
WTA were not protected against infection with tarP-expressing 
MRSA, indicating that TarP is crucial for the capacity of S. aureus 
to evade host defences. High-resolution structural analyses of TarP 
bound to WTA components and uridine diphosphate GlcNAc (UDP-
GlcNAc) explain the mechanism of altered RboP glycosylation and 
form a template for targeted inhibition of TarP. Our study reveals 
an immune evasion strategy of S. aureus based on averting the 
immunogenicity of its dominant glycoantigen WTA. These results 
will help with the identification of invariant S. aureus vaccine 
antigens and may enable the development of TarP inhibitors as a new 
strategy for rendering MRSA susceptible to human host defences.
Novel prevention and treatment strategies against major antibiotic- 
resistant pathogens such as MRSA are urgently needed but are not 
within reach because some of the most critical virulence strategies 
of these pathogens are not understood8. The pathogenic potential of 
prominent healthcare-associated (HA)-MRSA and recently emerged 
livestock-associated (LA)-MRSA strains is thought to rely on par-
ticularly effective immune evasion strategies, whereas community- 
associated (CA)-MRSA strains often produce more aggressive toxins1,2. 
Most humans have high overall levels of antibodies against S. aureus as a 
consequence of preceding infections, but antibody titres differ strongly 
for specific antigens and are often not protective in immunocompro-
mised patients, for reasons that are not clear3. A large percentage 
of human antibodies against S. aureus is directed against WTA5,9,10, 
which is largely invariant. However, some S. aureus lineages produce 
altered WTA, which modulates, for instance, phage susceptibility7,11.
To investigate whether some prevalent S. aureus lineages use additional 
WTA-targeted strategies to increase their fitness and pathogenicity, 
we screened S. aureus genomes for potential additional paralogues 
of WTA biosynthesis genes. We found three S. aureus prophages that 
encoded a protein, TarP, that has 27% identity to the WTA-β-GlcNAc 
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Fig. 1 | The phage-encoded TarP can replace the housekeeping WTA 
β-GlcNAc transferase TarS. a, TarP is encoded next to different integrase 
types (int gene) in prophages ϕtarP-Sa3int (with immune evasion 
cluster scn, chp, sak, sep), found in HA-MRSA, and ϕtarP-Sa1int and 
ϕtarP-Sa9int, identified in LA-MRSA. TarP variants in ϕtarP-Sa1int 
and ϕtarP-Sa9int differed from TarP in ϕtarP-Sa3int in one amino acid 
each (I8M and D296N, respectively). Both residues are distant from the 
catalytic centre. b, Complementation of S. aureus RN4420 ΔtarM/S with 
either tarS or tarP restores susceptibility to infection by WTA GlcNAc-
binding siphophages, as indicated by plaque formation on bacterial lawns. 
Data shown are representative of three independent experiments. c, tarP 
expression reduces siphophage Φ11-mediated transfer of SaPIbov in N315. 
Values indicate the ratio of transduction units (TrU) to plaque-forming 
units (PFU) given as mean ± s.d. of three independent experiments. 
Statistical significances when compared to wild type were calculated by 
one-way ANOVA with Dunnett’s post-test (two-sided) and significant  
P values (P ≤ 0.05) are indicated. NO (none obtained) indicates no 
obtained transductants.
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transferase TarS7 (Fig. 1a). tarP was found exclusively in isolates of the 
prominent HA-MRSA CC512, on a prophage that also encoded the 
scn, chp and sak immune evasion genes13, and on two other prophages 
in the emerging LA-MRSAs CC39814 and CC515. All tarP-harbouring 
genomes also contained tarS.
When tarP from CC5 HA-MRSA strain N315 was expressed in a 
WTA glycosylation-deficient mutant of laboratory strain RN42207, 
it restored WTA glycosylation (Extended Data Fig. 1a) and suscep-
tibility to siphophages, which need RboP WTA GlcNAc as a binding 
motif16 (Fig. 1b). The presence of β-GlcNAc on WTA is essential for full 
β-lactam resistance in MRSA strains7. When tarP was expressed in a 
WTA glycosylation-deficient mutant of CA-MRSA strain MW2 (CC1), 
it restored full oxacillin resistance (Extended Data Fig. 1b), confirming 
that tarP can replace tarS in several key interactions.
The expression of TarP led to susceptibility to siphophages, albeit to a 
lower extent than TarS (Extended Data Fig. 1c), although TarP did not 
incorporate less GlcNAc into WTA than TarS (Extended Data Fig. 1d, 
Supplementary Table 3). Similarly, the siphophage-mediated horizontal 
transfer of an S. aureus pathogenicity island was reduced about 
tenfold in S. aureus N315 expressing tarP, compared to the same strain 
expressing only tarS (Fig. 1c), suggesting that TarP and TarS glycosylate 
WTA differently. Notably, N315 was resistant to podophages, but inac-
tivation of tarP (but not of tarS) rendered it susceptible to podophages 
(Fig. 2a). We analysed the overall effect of tarP on podophage suscep-
tibility patterns in 90 clinical CC5 and CC398 isolates and found that 
none of the tarP-containing strains, but all of the tarP-lacking strains, 
were susceptible to podophages (Extended Data Table 1). Thus, TarP 
causes podophage resistance and TarP-mediated modification of WTA 
is distinct from that mediated by TarS. Nuclear magnetic resonance 
(NMR) analyses revealed that both TarP and TarS add GlcNAc to WTA 
in the β-configuration. However, the attachment site in RboP differs: 
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Fig. 2 | TarP protects N315 from podophage infection by alternative 
glycosylation of WTA at RboP C3. a, Expression of tarP renders N315 
resistant to podophages. Representative data from three independent 
experiments are shown. b, 1H NMR spectra reveal different ribitol 
hydroxyl glycosylation of N315 WTA by TarS (C4) or TarP (C3). The 
RboP units with attached GlcNAc are depicted above the corresponding 
proton resonances. Representative data from three experiments are shown. 
In-depth description of the structural motifs identified in the spectra 
is given in the Supplementary Information. c, Crystal structure of TarP 
homotrimer (pink, orange, grey) bound to UDP-GlcNAc (yellow) and two 
Mn2+ ions (lime green). The nucleotide-binding domain (NBD), acceptor-
binding domain (ABD), and C-terminal trimerization domain (CTD) of 
the pink monomer are labelled. d, Views into the trimer interface (boxed 
in c). Left, polar interactions. Hydrogen bonds and salt bridges are shown 
as black dashed lines. The Mn2+ is 2.1 Å from each Asp316 carboxylate. 
Right, hydrophobic interactions, with the mutated residue Ile322 
highlighted in red. e, Size-exclusion chromatography elution profiles. 
Based on calibration of the column, the TarP wild-type and I322E mutant 
proteins have estimated molecular weights of 138 kDa (n = 8) and 42 kDa 
(n = 3), respectively, in agreement with the calculated molecular weights of 
120 kDa for a TarP trimer and 40 kDa for monomeric TarP.
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to C3 (Fig. 2b, Extended Data Fig. 2, Supplementary Table 2). This 
difference may be crucial for impairing phage infection. Moreover, 
NMR analysis revealed that TarP is dominant over TarS because in 
N315, which bears both genes, GlcNAc was almost exclusively attached 
to RboP C3 (Fig. 2b).
We solved the TarP structure at high resolution to elucidate how TarP 
generates a different glycosylation product from TarS. Like TarS18, TarP 
forms stable homotrimers, but it uses a different trimerization strategy 
because it lacks the C-terminal trimerization domain found in TarS 
(Fig. 2c, Extended Data Fig. 3). Instead, hydrophobic and polar inter-
actions of a small helical C-terminal domain generate the TarP trimer 
(Fig. 2d, e). WTA polymers comprising three or six RboP repeating 
units (3RboP or 6RboP-(CH2)6NH2, respectively) were synthesized and 
used for soaking TarP crystals (Supplementary Information Fig. 2, 3), 
yielding the first protein structure visualizing the binding of a WTA-
based polymer (Fig. 3, Extended Data Fig. 4). In the ternary complex 
TarP–UDP-GlcNAc–3RboP, the distance between the C3-hydroxyl of 
the third unit of 3RboP (RboP3) and the anomeric C1 of GlcNAc is 
4.2 Å. Furthermore, at 3.1 Å, Asp181 is well within hydrogen bond-
ing distance of the C3-hydroxyl of RboP3. The observed distances 
and geometry nicely explain the unusual glycosylation of WTA at the 
C3-hydroxyl. We propose that TarP uses a direct SN2-like glycosyltrans-
ferase reaction, as discussed for other inverting GT-A fold enzymes19,20. 
In this mechanism, Asp181 would act as the catalytic base, deprotonat-
ing the C3-hydroxyl on RboP3 and enabling a nucleophilic attack on 
the GlcNAc C1, thus yielding a β-O-GlcNAcylated polyRboP (Fig. 3c). 
Mutagenesis of Asp181 to alanine rendered TarP inactive, supporting 
this putative mechanism (Extended Data Table 2).
The ternary structure of TarP–UDP-GlcNAc–3RboP allows us to 
predict how polyRboP binds to the homologous TarS enzyme. Three 
residues that are critical for binding and catalysis (including Asp181) 
are identical in TarP and TarS, while five other residues differ18 
(Fig. 3d). Lys255 and Arg262, for instance, which interact electrostat-
ically with a WTA phosphate group in TarP, are replaced with Glu248 
and Ser255, respectively, in TarS, which may lead to reduced affinity for 
WTA and might explain why TarP is dominant over TarS in vivo. On 
the basis of the location of UDP-GlcNAc, the identical Tyr149, Asp178 
and Arg252 side chains, the conserved aromatic side chain of Phe256, 
and a site that contains a bound sulfate ion from the crystallization 
solution (S1) and probably binds phosphate in TarS (Fig. 3e), the polyR-
boP chain would be shifted to the upper right, and the relative position 
of RboP units in the binding site would be altered in TarS. Such an 
altered binding mode would move the C4-hydroxyl of the target RboP 
towards C1 of GlcNAc, allowing TarS to glycosylate at the C4 position.
S. aureus WTA is a dominant antigen for adaptive immune 
responses5,9. The observation that the position of GlcNAc on RboP 
had a profound impact on binding by podophage receptors raises the 
question of whether human antibodies also discriminate between 
the two isomeric polymers and whether MRSA clones use TarP to 
subvert immune recognition. We analysed several human antibody 
Y149
TarP  S149 Y152 D181 K255 R259 R262 H263 T302 I304





















































Fig. 3 | Interactions of TarP with UDP-
GlcNAc and d-ribitol-5-phosphate trimer 
(3RboP), and comparison of polyRboP 
binding sites of TarP and TarS. a, 3RboP 
binding site in the TarP–3RboP complex, 
with key amino acids shown (cyan). Asp181 
is highlighted in red. The ribitol of 3RboP is 
coloured green and d-ribitol-5-phosphate 
units 1, 2 and 3 (RboP1, RboP2, and RboP3) 
are labelled. Hydrogen bonds and salt bridges 
are shown as black dashed lines. b, Ternary 
complex of TarP with UDP-GlcNAc and 3RboP. 
UDP-GlcNAc, Mg2+ and 3RboP are shown as 
full-atom models coloured yellow, magenta, 
and green, respectively. c, View into the active 
site of TarP. C1 of UDP-GlcNAc and Asp181  
are highlighted with red labels. The arrow 
indicates how the C3-hydroxyl in RboP3  
could nucleophilically attack GlcNAc C1.  
d, Comparison of the polyRboP-binding site 
of TarP with the corresponding region in TarS. 
Residues of TarP and 3RboP are coloured as in 
a. TarS residues are coloured violet and the two 
sulfates are labelled S1 and S2. Only residues 
of TarP are labelled, for clarity. Key TarP and 
TarS residues lining the polyRboP-binding site 
are shown at the bottom, with three identical 
(red) and one conserved amino acids (blue). 
e, Superposition of UDP-GlcNAc-bound TarS 
with the ternary TarP–UDP-GlcNAc–3RboP 
complex. UDP-GlcNAc and 3RboP bound 
to TarP are coloured as in b, whereas UDP-
GlcNAc bound to TarS is coloured in cyan. 
Only the TarS residues are shown (coloured as 
in d), for clarity. The arrows indicate the C1 
positions of UDP-GlcNAc in TarP and TarS.
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preparations for their capacity to opsonize a panel of N315 strains 
with or without tarP and/or tarS. The mutant lacking any WTA 
glycosylation bound the lowest amount of IgG compared to WTA 
glycosylation-positive strains (Fig. 4a), demonstrating that glyco-
sylated WTA is a prominent S. aureus antigen in humans. Exclusive 
expression of tarS led to strongly increased IgG binding compared 
to the glycosylation-deficient mutant, indicating that β-GlcNAc on 
RboP C4 is an important epitope for human anti-S. aureus anti-
bodies. By contrast, expression of tarP in the presence or absence 
of tarS led to only slightly increased IgG binding compared to the 
glycosylation-deficient mutant. The capacity of TarP to impair the 
deposition of IgG on S. aureus differed with individual serum donors 
and reached average levels in pooled serum preparations (Fig. 4a). 
When tarP was deleted in three further CC5 isolates, they showed 
similarly increased capacities to bind human serum antibodies com-
pared to the wild-type strains (Extended Data Fig. 1e). Additionally, 
tarP deletion led to a substantially increased capacity of human 
neutrophils to phagocytose opsonized S. aureus (Fig. 4b, Extended 
Data Fig. 1g). Thus, only a small percentage of S. aureus-specific 
antibodies can bind WTA with β-GlcNAc on RboP C3, and tarP- 
expressing S. aureus are less likely to be detected and eliminated by 
human phagocytes.
We purified N315 WTA that had been glycosylated by TarS or 
TarP and used it to immunize mice. Antibodies binding to regular 
(TarS-modified) WTA increased continuously over three weeks after 
vaccination (Fig. 4c). By contrast, no or only very low amounts of IgG 
directed against TarP-glycosylated WTA emerged, indicating that WTA 
modified at RboP C3 is much less immunogenic than WTA modified at 
RboP C4. This experiment was repeated three times with three different 
WTA preparations and yielded broadly similar data.
Vaccination with S. aureus WTA bearing GlcNAc at RboP C4 
protects mice against infection by CA-MRSA strains USA300 (CC8) or 
USA400 (CC1), which both lack tarP5,21. Remarkably, vaccination with 
regular (TarS-modified) or TarP-modified WTA did not lead to any 
notable protection against subsequent infection with tarP-expressing 
N315 compared to mock vaccination, despite the robust antibody 
response against regular WTA (Fig. 4d). Together, our results demon-
strate that tarP protects S. aureus against adaptive host defences 
by allowing bacteria to evade recognition by preexisting anti- 
S. aureus antibodies and by exploiting the poor immunogenicity of 
TarP-modified WTA.
It is possible that TarP-modified WTA mimics a currently unknown 
autoantigen and is therefore hardly immunogenic. On the other hand, 
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Fig. 4 | TarP attenuates immunogenicity of WTA. a, TarP expression 
reduces deposition of IgG from human serum on N315 cells. The protein 
A gene spa was deleted in all strains. Top, human IgG isolated from three 
individual healthy donors (A, B, and C; n = 4); bottom, left, IgG from 
human serum enriched for RN4220 WTA binding (n = 4); middle and 
right, pooled human IgG from different suppliers (Abcam, n = 4; Athens 
R&T, n = 6). Results were normalized against wild type and shown as 
means with s.d. of n experiments. P values for comparison with wild type 
were calculated by one-way ANOVA with Dunnett’s post-test (two-sided), 
and P ≤ 0.05 was considered significant. Significant P values are displayed. 
b, TarP reduces neutrophil phagocytosis of N315 strains lacking protein 
A, opsonized with indicated concentrations of IgG enriched for WTA 
binding. Values are depicted as mean fluorescence intensity (MFI). Means 
of two dependent replicates of a representative experiment are shown. 
The other two representative experiments can be found in Extended Data 
Fig. 1g. c, TarP abrogates IgG response of mice towards WTA. For each 
experiment, WTA from N315 ΔtarP or ΔtarS was isolated independently. 
At least three mice per group were vaccinated and analysed for specific 
IgG at indicated time points after vaccination. Results are depicted as 
mean absorbance with s.d. Individual mice are indicated by colour. 
Increase in IgG levels was assessed by one-way ANOVA with Tukey’s 
post-test (two-sided). Significant differences (P ≤ 0.05) are indicated 
with corresponding P values. d, Vaccination with WTA does not protect 
mice against tarP-expressing N315, as shown for bacterial loads in kidney 
upon intravenous infection. No significant differences between groups of 
either five vaccinated mice or four mice for the alum control group (means 
indicated), calculated by one-way ANOVA, were observed.
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and presented to T cells, in a largely unexplored way, thereby evoking 
specific immunoglobulins and immunological memory22,23. It is possi-
ble that TarP-modified WTA is refractory to this process. Thus, TarS- 
and TarP-modified WTA could be helpful for decoding glycopolymer 
presentation pathways and for defining the most promising WTA 
epitopes for the development of protective vaccines against S. aureus.
Protection against S. aureus infections is urgently needed, in particu-
lar for hospitalized and immunocompromised patients2,4. Antibodies 
can in principle protect against S. aureus, but their titres and specif-
icities vary largely among humans and they are often not protective 
in immunocompromised patients3, probably in particular against 
S. aureus clones that mask dominant epitopes, for instance using TarP. 
Unfortunately, all previous human vaccination attempts with protein 
or glycopolymer antigens have failed, for reasons that are unclear24. 
Our study identifies a new strategy used by pandemic MRSA clones to 
subvert antibody-mediated immunity, which should be considered in 
future vaccination approaches. S. aureus WTA with GlcNAc at RboP C3 
has been reported as a type-336 antigen, but was not further explored25. 
We found that tarP is present in type-336 S. aureus (Extended Data 
Fig. 1f). However, TarP-modified WTA is a very poor antigen and 
vaccines directed against GlcNAc at WTA RboP C3 or C4 may fail 
against many of the pandemic MRSA clones. The structural character-
ization of TarP will instruct the development of specific TarP inhibitors 
that could become important in combination with anti-WTA vaccines 
or antibiotic therapies. We found tarP-encoding prophages in 70–80% 
of south-west German HA-MRSA CC5 and 40% of Danish LA-MRSA 
CC398 isolates (Extended Data Table 1), pointing to a crucial role of 
tarP in the fitness of these lineages and raising concerns of further 
dissemination by horizontal gene transfer. TarP is a new and probably 
crucial component of the S. aureus virulence factor arsenal26,27, high-
lighting the important roles of adaptive immunity and its evasion in 
S. aureus infections.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments 
were not randomized. The investigators were not blinded to allocation during 
experiments and outcome assessment.
Bacterial strains and growth conditions. S. aureus strains N315, RN4220, and 
MW2 (wild type and mutants) were used for this study. Collections of CC5 isolates 
of the Rhine-Hesse pulsed-field gel electrophoresis type28 and of the LA-MRSA 
lineage CC398 from the Danish Statens Serum Institut29,30 were analysed for the 
presence of tarP and for podophage susceptibility. Additionally, 48 spa-type t002 
(ST5) and 16 spa-type t003 (ST225) isolates were obtained from the MRSA collec-
tion of the University Hospital Tübingen and analysed for tarP presence by PCR. 
S. aureus strains were cultivated in tryptic soy broth (TSB) or basic medium (BM; 
1% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.1% glucose, 0.1% K2HPO4, w/v). 
MICs of oxacillin were determined by microbroth dilution according to established 
guidelines31.
Experiments with phages. tarP-encoding phages were identified in genome 
sequences using the webtool Phaster32 in representative strains listed with 
GenBank accession: ΦtarP-Sa3int with immune evasion cluster (IEC) in 
CC5 (strain N315, BA000018.3), ΦtarP-Sa1int, found in LA-MRSA of CC5 
(strain ISU935, CP017090), and ΦtarP-Sa9int found in CC398 (strain E154, 
CP013218).
Phage susceptibility was determined using a soft-agar overlay method16. In brief, 
10 µl phage lysate of 104–106 PFU was dropped onto soft agar containing 100 
µl bacterial suspension (OD600 of 0.1). Plates were incubated at 37 °C overnight. 
The efficiency of plating was determined as described33. Transfer of SaPIs was 
determined according to previously described methods11. In brief, SaPI particle 
lysates were generated from S. aureus strain JP1794, which encodes a SaPI with a 
resistance marker for tetracycline34. PFU of SaPI lysate was determined on RN4220. 
200 µl bacterial culture (OD600 of 0.5) was mixed with 100 µl of SaPI particle lysate 
(SaPIbov1 (Φ11), 106 PFU/ml), incubated at 37 °C for 15 min. Appropriate dilu-
tions were plated on TSB plates containing 3 µg/ml of tetracycline, and CFU were 
checked after overnight incubation.
WTA isolation and structure analysis. WTA from S. aureus was isolated and 
purified according to previously described methods11. In brief, WTA was released 
from purified peptidoglycan by treatment with 5% trichloroacetic acid and dialy-
sed extensively against water using a Spectra/Por3 dialysis membrane (MWCO of 
3.5 kDa; VWR International GmbH). Obtained soluble WTA was quantified by 
determining the content of phosphate35 and GlcNAc36. For PAGE analysis of WTA, 
samples (400 nmol of phosphate per lane) were applied to a 26% polyacrylamide 
(Rotiphorese Gel 40 (19:1)) resolving gel and separated at 25 mA for 16 h37. The 
gel was equilibrated in a solution of 40% ethanol and 5% acidic acid at room tem-
perature for 1 h and the WTA ladders were visualized by incubation with alcian 
blue (0.005%) for several hours.
NMR spectroscopy experiments were carried out on a Bruker DRX-600 
spectrometer equipped with a cryo-probe, at 288 K (WT-WTA, TarS-WTA, and 
TarP-WTA) or 298 K (double-mutant WTA lacking any glycosylation). Chemical 
shifts of spectra recorded in D2O were calculated in p.p.m. relative to internal 
acetone (2.225 and 31.45 p.p.m.). The spectral width was set to 10 p.p.m. and the 
frequency carrier placed at the residual HOD peak, suppressed by pre-saturation. 
Two-dimensional spectra (TOCSY, gHSQC, gHMBC, and HSQC-TOCSY) were 
measured using standard Bruker software. For all experiments, 512 FIDs of 2,048 
complex data points were collected, 32 scans per FID were acquired for homo-
nuclear spectra, and 20 or 100 ms of mixing time was used for TOCSY spectra. 
Heteronuclear 1H-13C spectra were measured in the 1H-detected mode, gHSQC 
spectrum was acquired with 40 scans per FID, the GARP sequence was used for 
13C decoupling during acquisition; gHMBC scans doubled those of gHSQC spec-
trum. As for HSQC-TOCSY, the multiplicity editing during selection step version 
was used, scans tripled those of the HSQC spectrum and two experiments were 
acquired by setting the mixing time to 20 or 80 ms. During processing, each data 
matrix was zero-filled in both dimensions to give a matrix of 4K × 2K points 
and was resolution-enhanced in both dimensions by a cosine-bell function before 
Fourier transformation; data processing and analysis were performed with the 
Bruker Topspin 3 program.
Molecular biology. All primers used for PCR, cloning, and mutagenesis are 
listed in Supplementary Table 1. tarP (UniProt A0A0H3JNB0, NCBI Gene ID 
1260584) was amplified using genomic DNA of S. aureus N315 and inserted in 
Eschericha coli/S. aureus shuttle vector pRB47438 at the BamHI and SacI sites, to 
transform S. aureus, or into pQE80L at BamH1 and HindIII sites, to transform 
E. coli BL21(DE3). A thrombin cleavage site was inserted between the His-tag and 
mature protein in pQE80L. Single mutations of TarP were introduced by PCR-
based site-directed mutagenesis39. The obtained amplicons were confirmed by 
sequencing. For the construction of marker-less S. aureus deletion mutants of tarS 
or tarP, the pIMAY shuttle vector was used40. The IgG-binding surface protein A 
gene (spa) was deleted using the pKORI shuttle vector41. Protein A deletion had 
no impact on phage siphophage or podophage susceptibility, indicating that it did 
not alter WTA amount or structure.
Protein expression, purification, and activity assay. E. coli BL21(DE3) were grown 
in LB medium at 30 °C. Expression of tarP was induced with 1 mM IPTG at 22 °C at 
an OD600 of 0.6. After 15 h, cells were harvested, washed with wash buffer (50 mM 
Tris-HCl, pH 8.0, 1 mM EDTA), and lysed by sonication with lysis buffer (70 mM 
NaH2PO4, pH 8.0, 1 M NaCl, 20% glycerol, 10 U/ml of benzonase nuclease). 
After centrifugation (15,000g), the supernatant was filtered with a 0.45 µm filter, 
loaded onto a His Trap FF column (GE Healthcare, 5 ml), and washed with buffer 
A (50 mM NaH2PO4, pH 8.0, 1 M NaCl, 20% glycerol) supplemented with 45 mM 
imidazole and buffer B (buffer A with 90 mM imidazole). Finally, the protein was 
eluted with buffer C (buffer A with 500 mM imidazole), and the fractions were 
pooled, and further purified by size-exclusion chromatography on a Superdex 
200 10/30 column equilibrated with buffer D (20 mM MOPS, pH 7.6, 400 mM 
LiCl, 10 mM MgCl2, 5 mM β-mercaptoethanol, 5% glycerol). The peak fractions 
were pooled and concentrated to 1.4 mg/ml for crystallization. For selenomethio-
nyl-form TarP production, bacteria were grown in a selenomethionine-containing 
medium (Molecular Dimension) and auto-induction was carried out. The protein 
was purified as described above. The activity of wild-type and mutated TarP, as well 
as donor substrate specificity of TarP were determined with the ADP Quest Assay 
kit (DiscoverRx, Extended Data Tables 2, 3). The reaction volume was 20 µl with 
1 mM UDP-GlcNAc, 1.5 mM purified WTA from RN4220 ΔtarM/S. The reaction 
was started with protein and incubated at room temperature for 1 h. Released UDP, 
coupled into a fluorescence signal, was detected in a 384-well black assay plate with 
530 nm excitation and 590 nm emission wavelengths using TECAN Infinite M200.
Crystallization and data collection. Crystals were obtained by vapour diffusion 
at 20 °C. 1 µl protein solution was mixed with 1 µl reservoir solution containing 
25% PEG 3350, 250 mM MgCl2, and 0.1 M sodium citrate, pH 5.7. The selenome-
thionyl-form protein was crystallized under the same conditions. For crystals of 
TarP with UDP-GlcNAc, 27 mM UDP-GlcNAc was introduced in the reservoir 
solution containing 250 mM MgCl2 or 230 mM MnCl2. Crystals of TarP with Mg2+ 
were used for soaking of synthetic 3RboP (60 mM), 6RboP-(CH2)6NH2 (41 mM), 
or UDP-GlcNAc (20 mM) combined with 3RboP (52 mM) for 5 min. For data 
collection the crystals were cryo-protected with 20% glycerol in reservoir solution 
and flash-frozen in liquid nitrogen. Diffraction data were collected at beamline 
X06DA of Swiss Light Source in Villigen, Switzerland, or at beamline BL14.1 at 
BESSY-II, Helmholtz Zentrum Berlin.
Phasing, model building, and refinement. For phase determination, two data sets 
from a selenomethionine-containing TarP crystal were collected at wavelengths of 
0.97941 Å (peak) and 0.97952 Å (inflection). The structure was solved by multi- 
wavelength anomalous dispersion (MAD) at 2.60 Å resolution. All data were 
reduced using XDS/XSCALE software packages42. Initial phases were derived from 
the substructure of 26 selenium atom sites per asymmetric unit with the program 
suite SHELX C/D/E43. The heavy atom parameters were further refined and the 
initial phases were improved by SHARP/autoSHARP44. The initial model was 
generated with PHENIX45 and the final model was achieved by cycles of iterative 
model modification using COOT46, and restrained refinement with REFMAC. TLS 
was used in the later stages47,48. The four binary and one ternary complex structures 
were solved by molecular replacement using PHASER49 and the unliganded TarP 
structure was used as a search model. UDP-GlcNAc, 3RboP, Mg2+, or Mn2+ were 
removed from the models to calculate the simulated annealing (mFo − DFc) omit 
maps using PHENIX. The anomalous difference map of Mn2+ at 1.89259 Ǻ was 
generated by FFT within CCP4, from which two Mn2+ in the active site and one 
Mn2+ at the trimer interface were identified. The coordinate and parameter files 
for 3RboP and 6RboP-(CH2)6NH2 were calculated using the PRODRG server50. 
The structure figures were generated by PyMOL51 and the models were evaluated 
using MolProbity52. Statistics for the data collection, phasing, and refinement are 
reported in Extended Data Tables 4 and 5.
Synthesis of ribitol phosphate oligomers. Synthesis of 3RboP. Target compound 
1, d-ribitol-5-phosphate trimer (3RboP), was prepared by the phosphoramidite 
method53,54 (Supplementary Fig. 2). In brief, the primary alcohol of commercially 
available compound 2 was converted into levulinoyl ester by using levulinic acid 
and N,N'-dicyclohexylcarbodiimide (DCC), and the allyl group of 3 was removed 
with tetrakis(triphenylphosphine)palladium to produce compound 4. The primary 
alcohol of 4 reacted with phosphine derivative 5 in the presence of diisopropylam-
monium tetrazolide55 to generate phosphoramidite 6. At the same time, compound 4 
was coupled with dibenzyl N,N-diisopropylphosphoramidite 7, which was cata-
lysed by 1H-tetrazole, and the product was further oxidized by tert-butyl hydrop-
eroxide, yielding protected d-ribitol-5-phosphate 8. Cleavage of the levulinoyl ester 
of 8 with hydrazine hydrate resulted in benzyl protected d-ribitol-5-phosphate 9, 
which was further coupled with phosphoramidite 6 and oxidized with tert-butyl 
hydroperoxide to yield protected dimers of d-ribitol-5-phosphate 10. After removal 
of the levulinoyl group, the dimer 11 was coupled with phosphoramidite 6 using 
the same conditions as above to obtain a protected trimer of d-ribitol-5-phosphate 
© 2018 Springer Nature Limited. All rights reserved.
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12. Subsequent removal of the levulinoyl group and hydrogenolysis of 13 to remove 
all benzyl groups yielded 3RboP 1. All chemicals and experimental procedures as 
well as characterization of products can be found in the Supplementary Methods.
Synthesis of 6RboP-(CH2)6NH2. Aminohexyl d-ribitol-5-phosphate hexamer 
(6RboP-(CH2)6NH2) was synthesized using a new method (Supplementary Fig. 3). 
All chemicals (Acros, Biosolve, Sigma-Aldrich and TCI) for the synthesis were used 
as received and all reactions were performed under a protective argon atmosphere 
at room temperature, unless otherwise stated. Procedures for phosphoramidite 
coupling, oxidation, detritylation, global deprotection, TLC analysis and charac-
terization of these compounds can be found in Supplementary Methods.
Human samples. Venous blood samples were obtained from male and female 
healthy volunteers (20–50 years) with protocols approved by the Institutional 
Review Board for Human Subjects at the University of Tübingen (014/2014BO2 
und 549/2018BO2). Informed written consent was obtained from all volunteers. 
Blood samples were used for purification of either serum IgGs or neutrophils as 
described below.
IgG from human plasma. IgG was purified from plasma of human donors using 
the NAb Protein G Spin Kit (ThermoFisher), purity was checked by SDS PAGE, and 
protein concentration was determined using Bradford assay. Anti-WTA-IgG was 
prepared as described9. To analyse the IgG-binding capacity of S. aureus cells, expo-
nentially growing bacterial cultures were adjusted to an OD600 of 0.5, diluted 1:10 
in PBS, and 100 µl of diluted bacteria was mixed with 100 µl of IgG diluted in PBS 
with 1% BSA. The concentration of IgG was 250 ng/ml for IgG enriched for WTA 
binding, 10 µg/ml for IgG from pooled human serum (Athens R&T 16-16-090707, 
Abcam ab98981), or 5 µg/ml for single-donor IgG preparations. A control without 
IgG was included in all experiments for all mutants. Samples were incubated at 
4 °C for 1 h, centrifuged, washed 2–3 times with PBS, and further incubated with 
100 µl FITC-labelled anti-human IgG (Thermo Scientific, 62-8411, 1:100 in PBS 
with 1% BSA, 62-8411) at 4 °C for 1 h. Bacteria were centrifuged, washed 2–3 
times with PBS, and fixed with 2% paraformaldehyde (PFA). Surface-bound IgG 
was quantified by flow cytometry using a BD FACSCalibur. For all flow cytometry 
experiments a mutant panel lacking spa, the gene for the IgG-binding protein A, 
was used. The subsequent gating strategy is exemplified in Extended Data Fig. 5a.
IgG-mediated phagocytosis. Stationary-phase S. aureus cells were washed once 
with PBS and labelled by incubation in PBS containing 10 µM carboxyfluorescein 
succinimidyl ester (CFSE; OD600 of 1.7) at 37 °C for 1 h. The bacteria were washed 
three times and resuspended in PBS. CFU were determined by plating on TSB 
plates and bacteria were heat-inactivated at 70 °C for 20 min. CFSE-labelled 
S. aureus (1 × 107 cells/ml) in PBS with 0.5% BSA were opsonized with anti-WTA-
IgG (0.15 or 0.3 ng/µl) at 4 °C for 40 min. Neutrophils from human donors, isolated 
via Ficoll-Histopaque density gradient centrifugation56, were diluted to a con-
centration of 2.5 × 106/ml in neutrophil medium (10% HSA, 2 mM l-glutamine, 
2 mM sodium pyruvate, 10 mM HEPES). 200 µl neutrophil suspension was incu-
bated with 25 µl opsonized bacteria (final MOI 0.5) in a 96-well plate at 37 °C for 
30 min, centrifuged (350g, 10 min), washed once with 200 µl PBS, and fixed with 
2% PFA at room temperature for 15 min. Cells were washed twice with PBS and 
analysed by flow cytometry, whereby surface-bound and ingested bacteria were 
measured without discrimination. An example of the neutrophil gating strategy 
can be found in Extended Data Fig. 5b.
Mice. Six-week-old sex-matched wild-type C57BL/6J mice, purchased from 
ORIENT BIO (Charles River Breeding Laboratories in Korea), were kept in 
micro-isolator cages in a pathogen-free animal facility. The conducted experi-
ments were performed according to guidelines and approval (PNU-2017-1503) 
by the Pusan National University-Institutional Animal Care and Use Committee 
(PNU-IACUC). Sample size was chosen to obtain significant outcomes (alpha 
error ≤ 5%), based on results from previous experiments21. Experiments were 
performed in a non-blinded, non-randomized fashion.
Mouse vaccination and infection. 30 µg of purified WTA from S. aureus N315 
wild-type or isogenic ΔtarP, or ΔtarS mutants was dissolved in 15 µl PBS and 
mixed with the same volume of aluminium hydroxide gel adjuvant (Alhydrogelr 
1.3%, 6.5 mg/ml, Brennatag). The mixtures were incubated at 37 °C with agitation 
for 1 h and injected three times at one-week intervals via mouse footpads. Seven 
days after the third injection, blood was obtained from the retro-orbital sinus 
and centrifuged (9,000g) at 4 °C for 10 min. The supernatants were aliquoted 
(50 µl) and stored at –80 °C for ELISA quantification of WTA-binding IgG as 
described57. Sera were diluted 1:100 and tested by ELISA on 96-well plates coated 
with 2.5 µg/ml sonicated WTA preparations (WTA from N315, ΔtarS or ΔtarP, 
respectively).
To prepare an inoculum for infection, N315 wild-type bacteria were grown in 
TBS at 37 °C with agitation (180 r.p.m.) until they reached an OD600 of 1.0. After 
centrifugation (3,500g) at 4 °C for 10 min, bacteria adjusted to 5 × 107 CFU in 50 µl 
PBS containing 0.01% BSA were intravenously injected (n = 5 per group). Injected 
bacterial numbers were verified by plating serial dilutions of the inoculum onto 
TSA plates. To determine residual bacterial dissemination to kidneys, challenged 
mice were euthanized, and organs were extracted aseptically and homogenized 
in 1 ml of saline using a Polytron homogenizer (PT3100). The homogenates were 
serially diluted and plated on TSA to determine CFU counts. CFU were calculated 
per 1 ml of kidney.
Statistical analyses. Statistical analysis was performed by using GraphPad Prism 
(GraphPad Software, Inc.). Statistically significant differences were calculated by 
appropriate statistical methods as indicated. P values of ≤ 0.05 were considered 
significant.
Reporting summary. Further information on experimental design is available in 
the Nature Research Reporting Summary linked to this paper.
Data availability
All major data generated or analysed in this study are included in the article or 
its supplementary information files. The coordinates and structure factors were 
deposited in the Protein Data Bank under accession numbers 6H1J, 6H21, 6H2N, 
6H4F, 6H4M and 6HNQ. Source data for experiments with animals (Fig. 4c, d) 
are provided. Additionally, a gel image of Extended Data Fig. 1f is supplied as 
Supplementary Fig. 1. All other data relating to this study are available from the 
corresponding authors on reasonable request.
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Extended Data Fig. 1 | Characterization of TarP, deposition of human 
IgGs, and presence of tarP in the producer of antigen 336. a, Analysis 
of WTA by PAGE. WTA from RN4220 ΔtarM/S expressing either tarP 
or tarS was compared with non-glycosylated WTA. Data shown are 
representative of two experiments. b, MIC values of oxacillin against 
MW2 wild type, tarS mutant, and tarP-complemented tarS mutant. Data 
are medians of ten independent experiments. c, Efficiency of plating 
(EOP) of phage Φ11 against tarS or tarP-expressing RN4420 ΔtarM/S. 
Values of tarP relative to tarS expression are given as mean ± s.d. (n = 3). 
Statistical significance was calculated by paired Student’s t-test (two-
sided) with significant P values (P ≤ 0.05) indicated. d, The level of WTA 
glycosylation catalysed by TarP or TarS was determined by analysing the 
GlcNAc and phosphate content of WTA isolated from a N315 strain panel. 
Depicted is the ratio of GlcNAc and phosphate as mean with s.d. of three 
technical replicates. The values are in good agreement with NMR data 
(Supplementary Table 3). e, Relative deposition of IgG from intravenous 
immunoglobulins enriched for WTA binding on different CC5 wild-
type and tarP mutant cells. Values are given as mean percentage ± s.d. 
of four independent experiments. Statistical significance was calculated 
by paired Student’s t-test (two-sided). P values ≤ 0.05 were considered 
significant and are indicated. f, Presence of tarP and tarS in S. aureus 
ATCC55804, expressing antigen 336, described as 3-O-GlcNAc-WTA25. 
Shown is a representative of two independent replicates. g, TarP reduces 
neutrophil phagocytosis of N315 strains lacking protein A, opsonized 
with indicated concentrations of IgG enriched for WTA binding. Values 
are depicted as mean fluorescence intensity (MFI). Shown are two 
independent experiments with neutrophils from different donors. These 
data supplement data presented in Fig. 4b: upper panel, mean of three 
technical replicates of an independent experiment, lower panel, mean of 
two technical replicates.
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Extended Data Fig. 2 | NMR analysis of WTA from N315 mutant 
panel. All depicted experiments were repeated twice. y-axes and x-axes 
show 13C and 1H chemical shifts, respectively. a–d, NMR spectra of non-
glycosylated WTA (ΔtarSΔtarP mutant). a, HSQC expansion of the 
region containing the ribitol and glycerol protons shifted by acylation;  
b, c, HSQC-TOCSY-20 and HSQC-TOCSY-80 spectra, respectively.  
d, HSQC area of the non-acylated ribitol and glycerol proton. e–h, NMR 
spectra of TarS-WTA (ΔtarP mutant). e, HSQC expansion of the region 
containing the ribitol and glycerol protons shifted by acylation.  
f, g, HSQC-TOCSY-20 and HSQC-TOCSY-80, respectively. h, HSQC area 
of the non-acylated ribitol and glycerol proton. i–o, NMR spectra of TarP-
WTA (ΔtarS mutant). i, HSQC expansion of the region containing the 
ribitol and glycerol protons shifted by acylation. j, k, HSQC-TOCSY-20 
and HSQC-TOCSY-80 spectra, respectively. l, HSQC area of the non-
acylated ribitol and glycerol protons. m, Expansion of l with HSQC  
(black/grey) overlapped with HSQC-TOCSY-20 (cyan). n, Overlap of 
HSQC-TOCSY-20 (cyan) and HSQC-TOCSY-80 (black). o, HSQC (black) 
and HMBC (grey) detailing the GlcNAc signals. p, NOESY expansion 
detailing the correlations of the β-GlcNAc anomeric protons: GlcNAc ‘b*’ 
differs from unit ‘b’, which has the same anomeric proton chemical shift, 
but is linked to a different ribitol unit. All densities are labelled with the 
letters used in Supplementary Table 2. The density marked with an asterisk 
in m is consistent with ribitol glycosylated at O-4.
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Extended Data Fig. 3 | Secondary structure of a TarP monomer and 
interactions with UDP-GlcNAc. a, Cartoon representation of a TarP 
monomer bound to UDP-GlcNAc (yellow) and Mn2+ (lime green). The 
CTD is coloured red. b, Interactions of TarP with UDP-GlcNAc and Mn2+, 
coloured as in a. Hydrogen bonds and salt bridges are shown as black 
dashed lines. c, Interactions of TarP with UDP-GlcNAc (yellow)  
and Mg2+ (magenta). d, Simulated-annealing (mFo − DFc) omit map of 
UDP-GlcNAc (grey mesh, contoured at 2.0σ) and Mn2+ (magenta mesh, at 
3.0σ) in the TarP–UDP-GlcNAc–Mn2+ complex structure. UDP-GlcNAc 
and Mn2+ are coloured as in a. e, Simulated-annealing (mFo − DFc) omit 
map of UDP-GlcNAc (grey mesh, at 2.0σ) and Mg2+ (blue mesh, at 2.0σ) 
in the TarP–UDP-GlcNAc–Mg2+ complex structure. UDP-GlcNAc and 
Mg2+ are coloured as in c.
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Extended Data Fig. 4 | Simulated-annealing (mFo − DFc) omit maps 
of 3RboP and UDP-GlcNAc, and characterization of TarP mutant 
proteins. a, Chemical structures of synthetic 3RboP and 6RboP-
(CH2)6NH2. The unit numbers are indicated. b, Simulated-annealing 
(mFo − DFc) omit map of 3RboP (lime green) in the binary structure 
(magenta mesh, contoured at 2.0σ). c, Simulated-annealing (mFo − DFc) 
omit map of UDP-GlcNAc (yellow), Mg2+ (magenta) and 3RboP (lime 
green) in the ternary complex structure (red mesh, at 1.8σ, blue mesh, 
at 2.0σ or magenta mesh, at 1.5σ). d, Circular dichroism spectra of wild-
type and mutant TarP proteins (for wild type, R76A and D181A, n = 3; 
for D92A, Y152A and R259A, n = 2). e, Size-exclusion chromatography 
elution profiles of wild-type and mutant TarP proteins (for wild type, 
n = 8; for R76A, D181A and R259A, n = 3; for D92A and Y152A, n = 2, 
all with similar results). Mutant proteins D94A, E180A, D209A, K255A, 
R262A, and H263A showed similar circular dichroism spectra and size-
exclusion chromatography elution profiles (data not shown).
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Extended Data Fig. 5 | Gating strategy for flow cytometry experiments. 
a, Gating strategy for IgG deposition experiments. To distinguish bacteria 
from background signals, pure PBS was measured. Left, bacterial gating 
occurred at the FSC/SCC density plot omitting PBS-derived signals. 
Bacterial aggregates of high SSC and FSC values were excluded from the 
gated population as well. Right, the mean fluorescence of the bacterial 
population (black) was determined and compared with non-IgG-treated 
bacteria (grey) to control for nonspecific binding of the secondary FITC-
labelled antibody. Subsequently, mean fluorescence values of individual 
mutants were compared relatively to the corresponding wild-type strain.  
b, Gating strategy for phagocytosis experiments. Neutrophils were 
separated by Histopaque/Ficoll gradient and subsequent gating of 
neutrophils occurred at the FSC/SCC density plot upon size and 
complexity (left). Histopaque/Ficoll gradient isolations showed a 
neutrophil purity of more than 80%. Using the CFSE-fluorescence channel, 
the gated population was subdivided into fluorescence-positive and 
-negative cells (right). Successful phagocytosis was indicated by uptake 
of CFSE-labelled bacteria. The phagocytic efficiency was expressed as 
product of the mean fluorescence of the fluorescence-positive population 
and their relative abundance (mean fluorescence intensity, MFI).
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Extended data table 1 | tarP presence and podophage susceptibility of CC5 strains, comprising sequence type (St) 5 and 225, and CC398 
isolates
tarP presence in three different S. aureus collections was determined by PCR using primer pair TarP_Ty_Fw/Rv. Phage susceptibility to podophages Φ44, Φ66, and ΦP68 was determined by soft-agar 
overlay. Plaque formation indicated susceptibility, absence of visible plaque formation indicated resistance. ND, not determined.
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Extended data table 2 | Enzymatic activities of mutated tarP proteins
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Extended data table 3 | donor substrate specificity of tarP
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Extended data table 4 | Crystallographic data statistics for tarP and tarP–UdP-GlcNAc–Mg2+
Values in parentheses are for highest-resolution shell. Two data sets for TarP-SeMet were collected from the same single crystal.
*I is the mean intensity, σ(I) is the standard deviation of reflection intensity I.
**r.m.s.d., root-mean-square deviation of bond length or bond angle.
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Extended data table 5 | Crystallographic data statistics for tarP–UdP-GlcNAc–Mn2+, tarP–3RboP, tarP–6RboP-(Ch2)6Nh2 and  
tarP–UdP-GlcNAc–3RboP
Values in parentheses are for highest-resolution shell.
*I is the mean intensity, σ(I) is the standard deviation of reflection intensity I.
**r.m.s.d., root-mean-square deviation of bond length or bond angle.
© 2018 Springer Nature Limited. All rights reserved.
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main 
text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND 
variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Clearly defined error bars 
State explicitly what error bars represent (e.g. SD, SE, CI)
Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection - Genomes containing tarP were identified by the BLAST algorithm (URL: https://blast.ncbi.nlm.nih.gov/Blast.cgi), by using the amino acid 
sequence of TarP of S. aureus N315 (gene SA1808) as query. 
DA+ GUI, DA+ Server, Diffraction Viewer – Albula (version 3.2.0), and Data Processing Tracker were used for data collection of TarP 
structures at the beamline X06DA of Swiss Light Source in Villigen, Switzerland and Beamline-Control GUI (MXCuBE version 1) was used at 
the beamline BL14.1 in BESSY-II, Helmholtz Zentrum Berlin. For data reducing, phasing, model building, and refinement XDS package 
(BUTLT=20160617), XSCALE (BUTLT=20131111), SHELX C/D/E (2013/2), SHARP (2.8.6)/autoSHARP (3.10.6), PHENIX (1.13-2998), COOT 
(0.8.9.1 EL (CCP4)), REFMAC (CCPInterface 7.0.045), PHASER (CCP4Inetrface 7.0.044), FFT (CCP4Interface 7.0.052), CCP4 (7.0.062), 
PRODRG (CCP4Interface 7.0.062) were used. The structural figures were generated using PyMOL (1.8.4.1) and the models were valuated 
using MolProbity (4.02b-467). 
- NMR spectra were acquired, processed and analyzed by using Bruker TopSpin 3.1 software for WTA elucidation. For synthesis of 
chemical compounds Bruker TopSpin 2.1 was used.
Data analysis -tarP-containing genomes were analyzed by the web-tool PHASTER (URL: http://phaster.ca/).  
-Statistical analysis was performed by using GraphPad Prism (GraphPad 419 Software, Inc.) Version 6. 
- NMR spectra of WTA were analyzed by using Bruker TopSpin 3.1 software 
-Data analysis of NMR of chemical compounds MestReNova; Mnova 12.0.3 was used
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers 
upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All major data generated or analyzed in this study are included in the article or its supplementary information files. The coordinates and structure factors were 
deposited in the Protein Data Bank under accession numbers 6H1J, 6H21, 6H2N, 6H4F. and 6H4M and 6HNQ. Source data of experiments with animals (Fig 4c, d), 
and Gel electrophoresis (Extended data Fig. 1f) are provided as source data. All other data relating to this study are available from the corresponding authors on 
reasonable request. 
Field-specific reporting
Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size Sample sizes of in vitro and in vivo experiments were chosen to obtain significant results. The prospective power analysis was performed with 
appropriate statistical methods.
Data exclusions One data point ( =  one mouse) was not included in the alum control of experiment Fig 4d. The reason for exclusion was an early 
euthanization of the animal due to a severe abnormal infection. No data points from other in vitro or in vivo experiments were excluded. 
Replication Each major experiement was repeated at least three times as stated in the manuscript. In case of neutrophil phagocytosis assays results 
exhibited the typical strong donor-specific differences but similar trends between bacterial test strains. Therefore, a typical experiment, 
representative of 3 independet experiments is shown as stated in the figure legend. The other 2 replicates can be found in the Supplementary 
Information.
Randomization Neutrophils and plasma IgGs were obtained from three independent randomly selected donors to control for donor-specific differences in the 
prior exposure to S. aureus antigens. 
Blinding Blinding was not necessary in our study.
Reporting for specific materials, systems and methods
Materials & experimental systems
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Human research participants
Methods





Policy information about availability of materials
Obtaining unique materials Serum IgG was purified from plasma of ramdomly selected individual donors independently of sex or age. Remaining 
preparations are stored at -80°C and can be obtained upon request. 
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Antibodies used - IgG was isolated from plasma of individual donors via NAb 393 Protein G Spin Kit (ThermoFischer, Article number 89979) 
- Pooled human IgG preparations from different suppliers (Abcam, Article number ab98981, lot number not available); (Athens 
Research & Technology, Article Number 16-16-090707, Lot number IG2015-02) 
- IgG enriched for WTA binding, purified from IVIG in Pusan, South Koreas as described previously (Kurokawa et al., 2013 doi: 
10.1074/jbc.M113.509893) 
- Goat anti-Human IgG secondary antibody FITC conjugate (Thermo Scientific, Article Number 62-8411, Lot Number RH235723, 
SC242149,  and TF268287, Dilution 1:100 in 100 μL PBS per reaction, polyclonal) 
 
Validation - IgG isolated from plasma of idividual donors  was checked for purity by SDS PAGE 
- Pooled human IgG preparations were validated as stated by the manufacturers. Abcam: "Purity 96%. IgA and IgM levels are 
<1% of the total IgG content by RID. ab98981 shows a single band corresponding to gamma electrophoretic mobility by Cellulose 
Acetate Electrophoresis"; Athens Research & Technology: "Purity Greater than 95% by SDS-PAGE". 
- IgG enriched for WTA binding, purified from IVIG was checked for purity by SDS-PAGE as described previously (Kurokawa et al., 
2013 doi: 10.1074/jbc.M113.509893).
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals 6 weeks-old wild-type C57BL/6J mice of 50% male and 50% female ratio, 422 purchased from ORIENT BIO (Charles River 
Breeding Laboratories in Korea)
Wild animals The study did not involve wild animals.
Field-collected samples The study did not involve field-collected animals or organisms.
Human research participants
Policy information about studies involving human research participants
Population characteristics Individual donors of serum IgG and neutrophils were healthy volunteers selected randomly irrespective of sex and  age. Donors 
did not suffer from a documented  S. aureus infection.
Recruitment Donors of serum IgG and neutrophils were healthy volunteers selected randomly irrespective of sex. Donors were of 20-50 years, 




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation For IgG binding experiments, bacterial cultures were ajusted to an OD600 of 0.5, diluted 1:10 in PBS, and mixed with antibody 
solution in a ratio of 1:2. Samples were fixed with 2% paraformaldehyde prior to measurement. 
Instrument BD FACSCalibur Flow Cytometry,  model number 342976
Software CellQuest Pro version 5, FlowJo V10
Cell population abundance Neutrophils were isolated by Histopaque-Ficoll-gradient centrifugation and contaminating erythrocytes were lysed prior to 
analysis. Due to individual donor characteristics the samples contained an average of approximatly 65-70 % intact neutrophils, 
which were separated during measurement from cell debris/erythrocytes via FSC/SSC gating.  
In the FACS analysis, bacterial samples showed a purity of over 95%. Impurities were mainly caused by PBS-derived background 
signal. 
Gating strategy Neutrophil and bacteria gating occured at the FSC/SCC density plot. To distingush neutrophils from cell debris neutrophils were 
gated based on size and complexity. For bacterial cell gating, pure PBS was measured to define the background signal. 95% of 
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this background signal was excluded using a treshold on FSC and SSC. The bacteria were then gated according to their size and 
complexity. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
